Indications for LYRICA CR:
Neuropathic pain associated with diabetic peripheral neuropathy (DPN). Postherpetic neuralgia (PHN).
Swallow whole. Take once daily after evening meal. DPN: initially 165mg daily, may increase to max 330mg/day within 1 week. PHN: initially 165mg daily, may increase to 330mg daily within 1 week; max 660mg/day if insufficient relief after 2–4wks. Conversion from Lyrica capsules, oral soln: see full labeling. For all: renal impairment (CrCl 30–60mL/min): reduce dose (see full labeling); (CrCl <30mL/min or hemodialysis): dose with Lyrica.
LYRICA CR Warnings/Precautions:
Discontinue if angioedema, hypersensitivity reactions, myopathy or markedly elevated creatine kinase levels occur. Monitor for new or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood/behavior. Underlying respiratory depression; monitor and consider initiating at a low dose. CHF (w. NYHA Class III/IV status). Ocular conditions. Diabetes (monitor skin integrity). Avoid abrupt cessation (taper over ≥1 week). Pregnancy. Nursing mothers: not recommended.
LYRICA CR Classification:
Alpha-2 delta ligand.
LYRICA CR Interactions:
Increased risk for serious respiratory depression when concomitant CNS depressants, opioids. Potentiates CNS depression with alcohol, other CNS depressants. Additive edema, weight gain with thiazolidinediones. Increased risk of angioedema with concomitant ACEIs.
Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal (primarily difficulty with concentration/attention); elevated creatine kinase, decreased platelets, PR prolongation, male-mediated teratogenicity; may be tumorigenic. Also in children: increased appetite.
Register patients in North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334.
Caps—90; CR tabs—30; Soln—16oz